View in EDS

Generate what you can make: achieving in-house synthesizability with readily available resources in de novo drug design

Saved in:
Bibliographic Details
Title: Generate what you can make: achieving in-house synthesizability with readily available resources in de novo drug design
Authors: Alan Kai Hassen, Martin Šícho, Yorick J. van Aalst, Mirjam C. W. Huizenga, Darcy N. R. Reynolds, Sohvi Luukkonen, Andrius Bernatavicius, Djork-Arné Clevert, Antonius P. A. Janssen, Gerard J. P. van Westen, Mike Preuss
Source: Journal of Cheminformatics, Vol 17, Iss 1, Pp 1-16 (2025)
Publisher Information: BMC, 2025.
Publication Year: 2025
Collection: LCC:Information technology
LCC:Chemistry
Subject Terms: Computer-aided synthesis planning, Casp, Retrosynthesis, Synthesizability, Synthesizability score, De novo drug design, Information technology, T58.5-58.64, Chemistry, QD1-999
Description: Abstract Computer-Aided Synthesis Planning (CASP) and CASP-based approximated synthesizability scores have rarely been used as generation objectives in Computer-Aided Drug Design despite facilitating the in-silico generation of synthesizable molecules. However, these synthesizability approaches are disconnected from the reality of small laboratory drug design, where building block resources are limited, thus making the notion of in-house synthesizability with already available resources highly desirable. In this work, we show a successful in-house de novo drug design workflow generating active and in-house synthesizable ligands of monoglyceride lipase (MGLL). First, we demonstrate the successful transfer of CASP from 17.4 million commercial building blocks to a small laboratory setting of roughly 6000 building blocks with only a decrease of –12% in CASP success when accepting two reaction-steps longer synthesis routes on average. Next, we present a rapidly retrainable in-house synthesizability score, successfully capturing our in-house synthesizability without relying on external building block resources. We show that including our in-house synthesizability score in a multi-objective de novo drug design workflow, alongside a simple QSAR model, provides thousands of potentially active and easily in-house synthesizable molecules. Finally, we experimentally evaluate the synthesis and biochemical activity of three de novo candidates using their CASP-suggested synthesis routes employing only in-house building blocks. We find one candidate with evident activity, suggesting potential new ligand ideas for MGLL inhibitors while showcasing the usefulness of our in-house synthesizability score for de novo drug design. Scientific contribution Our core scientific contribution is the introduction of in-house de novo drug design, which enables the practical application of generative methods in small laboratories by utilizing a limited stock of available building blocks. Our fast-to-adapt workflow for in-house synthesizability scoring requires minimal computational retraining costs while supporting a high diversity of generated structures. We highlight the practicality of our approach through a comprehensive in-vitro case study that relies entirely on in-house resources, including in-silico generation, synthesis planning, and activity evaluation.
Document Type: article
File Description: electronic resource
Language: English
ISSN: 1758-2946
Relation: https://doaj.org/toc/1758-2946
DOI: 10.1186/s13321-024-00910-4
Access URL: https://doaj.org/article/f18cefe04320453db1f0f3f967700191
Accession Number: edsdoj.f18cefe04320453db1f0f3f967700191
Database: Directory of Open Access Journals
Description
Abstract:Abstract Computer-Aided Synthesis Planning (CASP) and CASP-based approximated synthesizability scores have rarely been used as generation objectives in Computer-Aided Drug Design despite facilitating the in-silico generation of synthesizable molecules. However, these synthesizability approaches are disconnected from the reality of small laboratory drug design, where building block resources are limited, thus making the notion of in-house synthesizability with already available resources highly desirable. In this work, we show a successful in-house de novo drug design workflow generating active and in-house synthesizable ligands of monoglyceride lipase (MGLL). First, we demonstrate the successful transfer of CASP from 17.4 million commercial building blocks to a small laboratory setting of roughly 6000 building blocks with only a decrease of –12% in CASP success when accepting two reaction-steps longer synthesis routes on average. Next, we present a rapidly retrainable in-house synthesizability score, successfully capturing our in-house synthesizability without relying on external building block resources. We show that including our in-house synthesizability score in a multi-objective de novo drug design workflow, alongside a simple QSAR model, provides thousands of potentially active and easily in-house synthesizable molecules. Finally, we experimentally evaluate the synthesis and biochemical activity of three de novo candidates using their CASP-suggested synthesis routes employing only in-house building blocks. We find one candidate with evident activity, suggesting potential new ligand ideas for MGLL inhibitors while showcasing the usefulness of our in-house synthesizability score for de novo drug design. Scientific contribution Our core scientific contribution is the introduction of in-house de novo drug design, which enables the practical application of generative methods in small laboratories by utilizing a limited stock of available building blocks. Our fast-to-adapt workflow for in-house synthesizability scoring requires minimal computational retraining costs while supporting a high diversity of generated structures. We highlight the practicality of our approach through a comprehensive in-vitro case study that relies entirely on in-house resources, including in-silico generation, synthesis planning, and activity evaluation.
ISSN:17582946
DOI:10.1186/s13321-024-00910-4